Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2CNS 2Other hematologic neoplasm 1Lymphoid 1

Conditions

Colorectal Neoplasms 47Pancreatic Neoplasms 43Neoplasm Metastasis 20Carcinoma, Hepatocellular 20Lung Neoplasms 15Ovarian Neoplasms 14Colonic Neoplasms 14Rectal Neoplasms 12Stomach Neoplasms 11Prostatic Neoplasms 11Melanoma 11Cholangiocarcinoma 11Carcinoma, Renal Cell 10Breast Neoplasms 10Sarcoma 8Lymphoma, Non-Hodgkin 8Glioma 8Carcinoma, Non-Small-Cell Lung 8Neuroblastoma 7Hepatoblastoma 7Esophageal Neoplasms 7Barrett Esophagus 7Anus Neoplasms 7Wilms Tumor 6Uterine Cervical Neoplasms 6Medulloblastoma 6Gastrointestinal Neoplasms 6Ependymoma 6Central Nervous System Neoplasms 6Adenocarcinoma Of Esophagus 6

Interventions

pembrolizumab 5Nivolumab 5Ipilimumab 4avelumab 3Neoadjuvant Therapy 3toripalimab 2durvalumab 2atezolizumab 2Specimen Handling 2Immune Checkpoint Inhibitors 2Celecoxib 2tislelizumab 1spartalizumab 1sintilimab 1regorafenib 1fludarabine phosphate 1fludarabine 1danvatirsen 1camrelizumab 1Taxes 1Surgical Procedures, Operative 1Radiation Dose Hypofractionation 1Paclitaxel 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Leucovorin 1Irinotecan 1Interleukin-2 1Immunoglobulin G 1IMM-101 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Turcot syndrome × Specimen Handling × Gastrointestinal × Clear all
NCT02359565 2026-05-13

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
71 enrolled
CNSGastrointestinal

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡